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Aims: To test prospectively whether healthy individuals with a family history of type 2 4 
diabetes are more susceptible to adverse metabolic effects during experimental overfeeding.   5 
Methods: We studied the effects of 3- and 28-days of overfeeding by 1250 kcal/day in 41 6 
sedentary individuals with and without a family history of type 2 diabetes (FH+ and FH-). 7 
Measures included weight, fat distribution (CT) and insulin sensitivity (hyperinsulinemic-8 
euglycemic clamp).   9 
Results: Body weight was increased at +3 and +28-days in both groups (p<0.001), with FH+ 10 
gaining significantly more weight at +28-days (3.4 ± 1.6 vs. 2.2 ± 1.4 kg, p=0.02).  Fasting 11 
serum insulin and C-peptide were increased at +3 and +28-days in both groups, with greater 12 
increases in FH+ for insulin at +3 and +28-days (p<0.01) and C-peptide at +28-days 13 
(p<0.05). Fasting glucose also increased at both time points, but without significant group 14 
effect (p=0.1). Peripheral insulin sensitivity decreased in the whole cohort at +28-days 15 




, p=0.03), and insulin sensitivity by HOMA-IR 16 
decreased at both time points (p<0.001) and to a greater extent in FH+ (p=0.008). Liver fat, 17 
subcutaneous and visceral fat increased similarly in both groups (p<0.001).  18 
Conclusions: Overfeeding induced weight and fat gain, insulin resistance and hepatic fat 19 
deposition in healthy individuals. However, individuals with a family history of type 2 20 
diabetes gained more weight and greater insulin resistance by HOMA-IR. This study suggests 21 
that healthy individuals with a family history of type 2 diabetes are predisposed to adverse 22 
effects of overfeeding.  23 
Trial registry number: NCT00562393 (www.clinicaltrials.gov).  24 
Key words: First-degree relatives of type 2 diabetes individuals; Insulin resistance, 25 




CT, computed tomography  30 
DSAT, deep subcutaneous adipose tissue 31 
DXA, dual energy X-ray absorptiometry  32 
FCS, fat cell size 33 
FH, family history 34 
FFM, fat free mass 35 
FM, fat mass 36 
GIR, glucose infusion rate 37 
HU, Hounsfield units  38 
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MUFA, monounsaturated fatty acid  39 
MRS, magnetic resonance spectroscopy 40 
NEAT, non-exercise activity thermogenesis  41 
PYY, peptide YY 42 
PUFA, polyunsaturated fatty acid  43 
SAT, subcutaneous adipose tissue  44 
SF, saturated fatty acid 45 
SSAT, superficial subcutaneous adipose tissue 46 





Over-nutrition and sedentary lifestyle are major causes of the obesity epidemic, which is 50 
associated with increased risk of related metabolic disorders including hypertension, coronary 51 
artery disease, insulin resistance and type 2 diabetes. First-degree relatives of individuals with 52 
a family history of type 2 diabetes (FH+) are at increased risk of developing type 2 diabetes 53 
[1, 2]. The mechanisms leading to this are not entirely clear, although defects already 54 
identified in this population include a greater tendency towards insulin resistance [2, 3], 55 
pancreatic beta cell impairment [4, 5], central adiposity [6], increased inflammation [7], 56 
increased intramyocellular lipid [8] and reduced mitochondrial function [8, 9]. We and others 57 
have also reported that these individuals have an impaired ability to respond to dietary 58 
challenge, including impaired fatty acid oxidation in response to a single high fat meal [10] or 59 
3-days isocaloric high fat feeding [11].  60 
 61 
Short term experimental overfeeding is a model often used in animal studies to induce insulin 62 
resistance and associated metabolic defects. In humans, this model was previously applied in 63 
lean healthy individuals. The observed outcomes from these studies include increases in 64 
fasting insulin and glucose [12], increases in energy expenditure [13] and intramyocellular 65 
triacylglycerol content [14] and decreases in peripheral [15] and hepatic insulin sensitivity 66 
[12]. The aim of the present study was to examine prospectively the effects of 3 and 28-days 67 
of overfeeding on body weight, fat distribution and insulin sensitivity and the relationships 68 
between these factors in healthy individuals with and without a family history of type 2 69 






Subjects Sedentary, non-smoking, non-diabetic men and women who either reported no 74 
family history of type 2 diabetes (FH-) or at least one first-degree relative with type 2 75 
diabetes (FH+) were recruited by advertisements in local newspapers. Subjects were excluded 76 
if weight had changed by > 2 kg in the preceding 6-months, if they exercised more than 60 77 
min per week, if they were taking medications known to affect insulin sensitivity or blood 78 
pressure or if they had a personal history of type 2 diabetes or cardiovascular disease. Forty 79 
one individuals were recruited; one male FH- subject did not complete the study due to a viral 80 
infection. The study protocol was approved by the Human Research and Ethics Committee at 81 
St Vincent’s Hospital, Sydney. Subjects provided informed written consent before 82 
commencement. The study was registered as a Clinical Trial at www.clinicaltrials.gov, 83 
registration# NCT00562393.  84 
Diets  Estimated energy requirements were calculated for each subject based on fat-free mass 85 
(FFM) and fat mass (FM) using equations previously generated by doubly-labelled water and 86 
intake-balance techniques [16-18]. A trained dietician then planned individual menus for 87 
participants. Study timeline and food consumption regimen are outlined in Fig 1. Briefly, 88 
complete 3-day food intakes were supplied to each participant before each metabolic study 89 
such that from day -3 to day 0 all foods were provided at baseline energy requirements with a 90 
nutrient composition of 30% fat, 15% protein and 55% carbohydrates. On days 0 - 3 and 25 - 91 
28 all foods were provided at baseline energy requirements plus 1250 kcal/day with a nutrient 92 
composition of 45% fat, 15% protein and 40% carbohydrates. During the overfeeding phase 93 
we aimed to double the amount of fat intake by providing 3 high energy-high fat snacks per 94 
day, each providing ~250 kcal (e.g. potato crisps, chocolate bars, cheesecake) and a liquid 95 
oil-based supplement (Benecalorie®, Novartis, Basel, Switzerland, 330 kcal) mixed in a 96 
dairy dessert (~200 kcal).  On days 3 – 25 of overfeeding, subjects were instructed to 97 
consume their regular diets and were provided with the above snacks and supplement to 98 
achieve an intake of 1250 kcal/day above baseline energy requirements. They were required 99 
to fill out checklists daily reporting which snacks were consumed, complete 3-day diet diaries 100 
once before study commencement and twice during the overfeeding phase and to meet the 101 
study dietician weekly. The checklists were reviewed during weekly weigh-ins by the study 102 
dietician so that any deviations from protocol were quickly identified and alternative options 103 
could be provided, to improve adherence to the diet plan. Diets were analysed for 104 
macronutrients and fatty acid composition using FoodWorks 2007 based on the Australian 105 
foods database (Xyris Software). Thirty two subjects returned the diet diaries of both study 106 
phases (Table 1).  107 
 108 
Metabolic Testing Subjects attended the clinical research facility at 8am after a 12-hour 109 
overnight fast at baseline, +3 and +28-day of overfeeding (Fig 1). Baseline and +28-day visits 110 
were identical; weight, height, blood pressure were measured in a hospital gown after voiding 111 
and fasting blood samples were drawn. After 30 min supine rest, resting metabolic rate 112 
(RMR) and RQ were determined for 30 min (ParvoMedics Inc. UT, US). A peri-umbilical 113 
subcutaneous fat biopsy was performed as described previously [19]. Insulin sensitivity was 114 




), as 115 
previously described [10]. Glucose was infused at a variable infusion rate to maintain glucose 116 
at 5.0 mmol/l and the steady state glucose infusion rate (GIR) was calculated between 90 and 117 
120 min. Indirect calorimetry was repeated in conjunction with the steady state measurement. 118 
Stanford 7-day activity recall tests were also administered at baseline and after 28-days of 119 
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overfeeding [20]. At +3-days of overfeeding, weight and blood pressure were measured, 120 
fasting blood samples were obtained and indirect calorimetry performed. Subjects attended 121 
the Clinical Research Facility weekly for weight follow-up, snack collection and consultation 122 
with the study dietician. 123 
  124 
Body Composition Fat mass, fat-free mass and central abdominal fat were assessed at 125 
baseline and +28-day of overfeeding by dual energy X-ray absorptiometry (DXA, Lunar 126 
DPX-Lunar Radiation, Madison WI), as previously described [21]. Three cross-sectional 127 
computed tomography (CT) scans (Phillips Gemini GXL), 1cm-width, centred on the L2-L3 128 
and L4-L5 disc space, and the T12-L1 disc space were also performed to assess abdominal 129 
adipose tissue distribution and hepatic fat content. Abdominal areas of adipose tissue were 130 
defined by attenuation values of  -50  to  150 Hounsfield units (HU), as previously described 131 
[19]. CT images were analysed using Gemini (GXL Host System). Two subjects did not 132 
undergo CT scans. L4-L5 superficial and deep subcutaneous adipose tissue were not analysed 133 
in 4 subjects and the spleen was not visualised in 2 subjects. 134 
 135 
Fat Cell Size Measure Subcutaneous adipose biopsies were fixed in Bouin’s, dehydrated, 136 
paraffin embedded and then sectioned (4µm thick). Sections were stained with haematoxylin 137 
and eosin. Digital images were captured using a camera (triCCD; Sony, Paris, France) and 138 
diameters measured using Perfect Image software (Claravision, Orsay, France). Fat cell size 139 
(FCS) was measured in 31 subjects who had histological samples available pre- and post- 140 
intervention. Adipocyte diameter measurement was performed blindly and for at least 2 fields 141 
of view. The mean diameter was calculated from an average of 400 cells per sample. 142 
 143 
Biochemical Analysis Glucose was analysed using a glucose oxidase electrode (YSI Life 144 
Sciences). Fasting serum insulin, C-peptide and leptin were assayed by radioimmunoassay 145 
(Linco Research, St Charles, USA). HOMA-IR was calculated as [fasting insulin 146 
(mU/l)*fasting glucose (mmol/l)]/22.5.   HDL cholesterol and triacylglycerol were evaluated 147 
by enzymatic colorimetry (Roche, Indiana, USA). LDL was calculated by the Friedewald 148 
equation. NEFA were measured by enzymatic colorimetry assay (Wako, Osaka, Japan).  149 
Statistical Analysis Data is presented as mean ± SD unless otherwise stated. Statistics were 150 
analysed with SPSS 15 (Chicago, IL). Leptin and insulin data were not normally distributed 151 
and log transformed for analysis. Baseline differences between groups were analysed by one-152 
way ANOVA. All other data was analysed using repeated measures with respect to group and 153 
time, and an intention to treat approach without carrying forward data on the one dropout. 154 
Bonferroni post-hoc was performed and further analysis was performed by independent t-test.  155 
Linear regression at baseline (n = 41) was used to generate equations for predicting RMR 156 
with FFM and FM in the model as previously described [16]. Correlations were performed 157 






Baseline Characteristics  162 
Baseline characteristics by group are shown in Table 2. There were no detectable differences 163 
between groups at baseline with respect to age, weight, BMI, blood pressure, fasting glucose, 164 
insulin, C-peptide, leptin, lipid profile or peripheral insulin sensitivity. The only difference 165 
was reduced carbohydrate oxidation in response to insulin infusion during the 166 
hyperinsulinemic-euglycemic clamp (∆RQ) in FH+. At baseline, peripheral insulin sensitivity 167 
was related to liver/spleen ratio (r = 0.5, p = 0.001) and visceral adipose tissue (r = -0.4, p = 168 
0.01).  Fat cell size correlated with percent body fat by DXA (r = 0.4, p = 0.04), subcutaneous 169 
adipose tissue (r = 0.4, p = 0.02), serum NEFA (r = 0.4, p = 0.02), triacylglycerol (r = 0.5, p = 170 
0.006) and insulin resistance by HOMA-IR (r = 0.5, p = 0.007). 171 
Diet Diary and Physical Activity Questionnaire Analysis 172 
Reported dietary intakes at baseline and during overfeeding by group are given in Table 1. 173 
Dietary fat (g) approximately doubled in the overfeeding phase. Carbohydrate and protein 174 
intake also increased (p <0.0001). There were no significant differences in energy, 175 
carbohydrate or protein intake between groups, although a tendency was noted for FH+ to 176 
consume more total energy (p = 0.15) and more fat during overfeeding (p = 0.07). The 177 
average self-reported consumption of snacks during the overfeeding period was 92±14 and 178 
95±9% in FH- and FH+, respectively (p = 0.4). Reported levels of physical activity were 179 
similar at baseline (230±8 and 232±12 METs-hr/week, in FH- and FH+, respectively, p = 0.7) 180 
and did not change with overfeeding (229±7 and 231±7 METs-hr/week, in FH- and FH+ 181 
respectively, time p = 0.4, group p = 0.8).  182 
Weight and Fat Distribution Changes in Response to Overfeeding 183 
As expected, overfeeding resulted in significant weight gain at +3 and +28-days (Fig 1A). At 184 
3-days, weight gain was not different between groups. At 28 days, FH+ individuals had 185 
gained 1.2 kg more than FH- individuals (p = 0.03). Weight gained as percentage of baseline 186 
weight was 0.7±0.9 and 1.0±0.7% in FH- and FH+ at +3-days, respectively (p = 0.4) and 187 
3.1±2.0 and 4.4±2.0% in FH- and FH+ at +28-days, respectively (p = 0.05). Fat mass, fat-free 188 
mass, central fat by DXA and visceral and subcutaneous adipose tissue volume by CT 189 
increased similarly in both groups (Table 3). Circulating leptin increased significantly with 190 
weight gain and to a greater extent in FH+ at +28-days (Fig 1B), consistent with greater 191 
weight gain in this group. The increase in circulating leptin at +3- and +28-days correlated 192 
with weight gain at these time points (r = 0.3, p = 0.03 and r = 0.5, p = 0.003, at +3- and +28-193 
days, respectively). A preferential fat gain in the L2-L3 visceral depot was observed in the 194 
whole cohort increasing from 33±15% at baseline to 34±14% at +28-days of overfeeding (p = 195 
0.008). However, this was abolished when baseline visceral volume was included as a 196 
covariate (p = 0.1). Liver fat increased significantly in response to overfeeding similarly in 197 
both groups (Table 3) and correlated with weight gain (R
2
 = 0.17, p = 0.01). Abdominal fat 198 
cell size did not change (Table 3).  199 
Metabolic Responses to Overfeeding 200 
Fasting glucose increased significantly at +3 and +28-days of overfeeding (p <0.01), but this 201 
response was not statistically different between groups (Fig 1C, p = 0.1). Fasting insulin and 202 
C-peptide increased at +3 and +28-days of overfeeding (Fig 1D and 1E), with a greater 203 
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increase in insulin in FH+ individuals at both time points (p <0.01, Fig 1D) and in C-peptide 204 
at +28-days (p <0.05, Fig 1E). Accordingly, HOMA-IR (reflecting fasting insulin resistance) 205 
increased significantly in both groups (p <0.005 for both time points; Fig 1F), with the 206 
increase more pronounced in FH+ individuals (p = 0.003, Fig 1F). Peripheral insulin 207 
sensitivity measured by the hyperinsulinemic-euglycemic clamp at +28-days decreased 208 





days of overfeeding (p = 0.03), but was not different between groups. Total and HDL-210 
cholesterol were significantly increased in response to overfeeding similarly in both groups 211 
(4.6±1.0 to 4.8±1.0, p = 0.01 for cholesterol and 1.3±0.3 to 1.4±0.4, p <0.0001 for HDL). 212 
Blood pressure, LDL-cholesterol and triacylglycerol levels were unchanged (data not shown). 213 
Fasting NEFA levels were significantly suppressed at +3-days (p <0.001) and returned to 214 
basal at +28-days overfeeding, without group effect (p = 0.4, Fig 1G). Plasma NEFA were 215 
suppressed at the hyperinsulinemic state (by clamp) at both baseline and +28-days of 216 
overfeeding (p <0.0001), without group difference at both time points (data not shown). 217 
Similarly, fasting RQ increased at +3-days (p <0.0001) and returned to basal at +28-days, 218 
without group effect (p = 0.8, Fig 1H). The ∆RQ during the clamp was not altered by 219 
overfeeding (data not shown). Baseline absolute RMR was not different between groups 220 
(Table 2) and increased at +3-days in both FH- and FH+ (1315±260 to 1370+265 kcal/d and 221 
1440±160 to 1530±195 respectively, p = 0.01) and at +28-days (1375±250 and 1525±220 222 
kcal/day in FH- and FH+ respectively, p = 0.01). Baseline RMR adjusted for FFM was not 223 
different between groups or in response to overfeeding (data not shown).  We also calculated 224 
predicted RMR at 28-days based on equations derived at baseline (RMR = 225 
158.8+19.91*FFM+10.37*FM), as previously described [16] and found no difference 226 
between the predicted and measured RMR at +28-days overfeeding (data not shown). We did 227 
not perform DXA measures at day 3 but repeated this analysis using body weight at baseline 228 
(RMR = 344.9+14.0*Weight). Similarly, we found no difference at 28-days. However, at day 229 
3, measured RMR (1454±40 kcal/day) was significantly elevated above weight-predicted 230 
RMR (1384±26 kcal/day). There was no difference between groups in this response (data not 231 
shown). The increase in thermogenesis in response to insulin infusion was 114 ± 164 232 
kcal/day at baseline and 125 ± 148 kcal/day at overfeeding, both were not different between 233 





High fat overfeeding induces insulin resistance in rodent models in as little as 3-weeks [22, 237 
23]. In this study, we established that 28-days of overfeeding induced weight gain and 238 
peripheral insulin resistance in healthy non-diabetic individuals. We also showed that fat was 239 
deposited in the liver and we established that individuals who report a family history of type 240 
2 diabetes gained more weight and developed greater insulin resistance by HOMA-IR when 241 
provided with identical dietary instructions.  242 
This is the first study to compare the effects of experimental overfeeding in individuals with 243 
and without a family history of type 2 diabetes and we observed that weight gain was higher 244 
in FH+ individuals. Moreover, since overconsumption of 10.5 kcal is required to gain 1 g of 245 
body weight [24, 25] and assuming no compensatory change in energy expenditure, we 246 
predicted a maximum weight gain of 3.3 kg with 28-days of overfeeding. We observed that 247 
FH+ individuals gained approximately the predicted weight whereas FH- individuals gained 248 
less than predicted. It should be emphasised that participants were free-living and self 249 
selecting their foods for most of the study. Therefore, this difference may be explained by 250 
dietary compliance and may suggest that FH- individuals are less able to over eat. Consistent 251 
with this, a trend towards greater fat and energy consumption was observed in FH+ 252 
individuals. This outcome is of great interest as identical dietary instruction and food options 253 
were provided to both groups. Although FH+ gained on average 1.2 kg more at day 28, we 254 
did not detect significant group differences in the compartmental gain by CT and DXA. This 255 
apparent inconsistency may stem from the lower reproducibility and higher variability of 256 
DXA [26] and CT estimates as compared to a single scale weight. Interestingly, we have 257 
previously reported impaired peptide YY (PYY) secretion in response to a meal in FH+ 258 
individuals [27], which may contribute to reduced satiety and facilitate weight gain. Even the 259 
classical experimental overfeeding studies [28-30] in which participants were incarcerated 260 
and all foods were provided, have shown wide variability in weight gain in response to 261 
controlled overfeeding. Furthermore, the experimental weight gain study in twins 262 
demonstrated a heritable component to weight gain with a much greater variability in weight 263 
gain between, than within, twin pairs [30]. In those studies, since energy intake was very 264 
carefully controlled, it is likely that differences in weight gain were due to variations in 265 
thermogenic response to overfeeding and possibly non-exercise activity thermogenesis 266 
(NEAT) [31]. In this study, we can establish that the weight gain differences between groups 267 
were not due to differences in compensatory changes in resting energy metabolism or 268 
physical activity levels by questionnaire, since more complex measures of activity were not 269 
used.    270 
Overfeeding increased fasting insulin, glucose and peripheral insulin resistance in the whole 271 
cohort. This is consistent with previous studies of short-term (3-days) [15] and long-term 272 
(4.5-months) overfeeding [32] in healthy lean men. Our initial hypothesis was that FH+ 273 
would have greater metabolic defects associated with overfeeding. Indeed, we observed that 274 
fasting serum insulin and C-peptide increased more in individuals with a family history of 275 
type 2 diabetes. Fasting blood glucose tended to increase more in FH+ individuals at +3-days 276 
of overfeeding and may account for the significant increase in insulin in this group. Notably, 277 
the insulin increase was maximal after just 3 days of overfeeding, which was during a time 278 
when all foods were provided to participants and prior to any detectable weight gain 279 
differences between groups.  Consistently, in response to 5-days overfeeding, healthy lean 280 
men increased insulin secretion during IVGTT [12]. In longer term overfeeding studies, 281 
reduced insulin clearance was observed after 4.5-months and significant weight gain in lean 282 
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young men [32]. These findings are similar to those in moderately fat fed dogs, where an 283 
initial increase in beta cell secretion is observed at 6-weeks, which is no longer evident at 3-284 
months when hyperinsulinemia is maintained via reduced insulin clearance by the liver [33].  285 
There is increasing evidence to suggest that the location of fat deposition may be more 286 
important than the total amount of fat stored in obese individuals [19]. For example, ectopic 287 
deposition of lipid within the liver is closely associated with traits of the metabolic syndrome 288 
[19, 34]. Consistent with this, we also observed a relationship between liver fat by CT and 289 
peripheral insulin resistance in this non-diabetic cohort at baseline. Gold-standard measures 290 
of liver fat were not conducted in the present study however, findings by magnetic resonance 291 
spectroscopy (MRS) and CT measurement of liver fat content are closely correlated [35]. 292 
Interestingly, we observed that deposition of fat within the liver was increased in response to 293 
28-days of overfeeding and although we did not detect a difference between groups, the 294 
increase in fat was closely aligned with the amount of weight gained. Deposition of fat in the 295 
liver in response to overfeeding has previously been shown in high fat fed rodents and dogs 296 
[36, 37] and in response to 3-day high fat-high energy diet in healthy lean men by MRS [38]. 297 
Interestingly, moderate calorie restriction for 2-days decreases liver fat in the obese [39]. 298 
Increased visceral fat is also closely associated with insulin resistance [40] and increased 299 
visceral adipose tissue is observed in BMI-matched insulin resistant FH+ individuals [6]. In 300 
this study, visceral adiposity was similar between groups at baseline and FH+ individuals 301 
were not more likely to deposit fat in the visceral compartment in response to overfeeding.  302 
Increased fat cell size is also observed in insulin resistance and may represent the failure of 303 
the adipose tissue mass to expand to accommodate increased energy intakes [19]. We did not 304 
detect an increase in average FCS with the moderate weight gain achieved in this study. This 305 
result is in contrast to an historical experimental overfeeding study [28], but that intervention 306 
was longer with much higher weight gain.  307 
There is some evidence to suggest that post-obese individuals do not appropriately oxidise 308 
dietary fat, which may predispose them to weight regain [41]. There is also marked 309 
variability in the capacity to switch appropriately between fat and carbohydrate oxidation 310 
between individuals [42]. This response has been termed metabolic flexibility [43] and has 311 
been associated with insulin resistance [11] and may also predispose to weight gain.  In this 312 
study, we observed impaired metabolic flexibility in response to insulin infusion in FH+ at 313 
baseline. However, this defect was not altered by overfeeding and there was no difference 314 
between groups in the fasting rates of fatty acid oxidation at baseline or during overfeeding 315 
and thus is unlikely to have contributed to increased weight gain observed in FH+. 316 
Overfeeding initially suppressed fatty acid oxidation. This may be due to suppressed lipolysis 317 
of adipose tissue as evidenced by reduced plasma NEFA and mediated by the increase in 318 
insulin.  Interestingly, fasting levels of fat oxidation and plasma NEFA returned to basal by 319 
28-days despite continuation of overfeeding, possibly as peripheral insulin resistance 320 
increased.  321 
In conclusion, short-term overfeeding induced insulin resistance and deposition of fat in the 322 
liver in healthy men and women. Individuals with a family history of type 2 diabetes were 323 
more susceptible to weight gain and developed greater insulin resistance by HOMA-IR which 324 
was evident even prior to any detectable difference in weight gain. This study suggests that 325 
healthy individuals with a family history of type 2 diabetes are predisposed to adverse effects 326 
of overfeeding, which may help explain their susceptibility to develop type 2 diabetes in an 327 
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Table 1 Diet diaries analysis at baseline and during overfeeding by group 338 
 FH- FH+ p 
 Baseline Overfeeding Baseline Overfeeding Time Group 
Energy (kcal) 1900±590 2890±640 2080±630 3360±910 0.0001 0.15 
Fat (g) 76±28 148±35 79±33 167±36 0.0001 0.07 
PUFA (g) 13±7 17±5 12±7 18±5 0.001 0.4 
MUFA (g) 28±10 71±19 28±12 80±14 0.0001 0.1 
SF (g) 28±12 50±15 31±16 59±18 0.0001 0.2 
Carbohydrate (g) 202±58 258±62 225±66 321±130 0.0001 0.2 
Protein (g) 84±32 113±36 99±38 131±30 0.0001 0.8 
Alcohol (g) 5±9 5±8 7±9 5±7 0.3 0.4 
Data based on n = 32 (19 FH- and 13 FH+) 339 





Table 2 Baseline characteristics of study participants 343 
 Whole cohort FH- FH+ p 
M/F 21/20 12/12 9/8  
Age 37±12 37±12 38±12 0.7 
Weight (kg) 75.0±12.0 73.5±13.0 77.3±10.0 0.3 
BMI (kg m
-2
) 25.6±3.5 25.1±3.1 26.4±4.1 0.3 
Systolic BP (mmHg) 113±12 110±13 117±10 0.08 
Diastolic BP (mmHg) 72±9 72±10 73±7 0.6 
Glucose (mmol/l) 4.5±0.4 4.5±0.4 4.5±0.2 1 
Insulin (pmol/l) 69.5±23.7 70.2±27.5 68.6±17.6 0.8 
C-peptide (pmol/l) 496±13 486±179 510±145 0.6 





) 54.0±18.2 56.4±19.7 50.7±15.7 0.3 
HDL (mmol/l) 1.3±0.3 1.3±0.4 1.2±0.3 0.2 
LDL (mmol/l) 2.8±0.9 2.7±0.9 2.9±0.9 0.3 
Cholesterol (mmol/l) 4.6±1.0 4.5±1.1 4.7±1.0 0.5 
Triacylglycerol (mmol/l) 1.1±0.4 1.1±0.4 1.2±0.5 0.5 
RMR (Kcal/day) 1388±222 1344±28 1443±30 0.2 
RQ basal 0.81±0.04 0.80±0.04 0.81±0.03 0.7 
RQ Clamp 0.10±0.04 0.11±0.05 0.09±0.03 0.04 




Table 3 Body weight, percent body fat and central fat (by DXA), abdominal fat distribution 346 
and liver density (by CT) and fat cell size at baseline and post 28-days of overfeeding in 347 
subjects with or without a family history of type 2 diabetes  348 
 FH- FH+ p 
 Baseline Overfeeding Baseline Overfeeding Time Group 
Weight (Kg) 73.9±13.1 76.1±13.3 77.3±10.0 80.7±10.4 0.0001 0.02 
Fat mass (%) 33±9 34±8 34±7 35±7 0.0001 0.9 
Fat-free mass 
(Kg) 
48.1±9.3 48.6±9.5 49.8±7.6 50.8±7.5 0.0001 0.2 
Central fat (kg)* 1.8±0.8 1.9±0.7 2.2±0.8 2.4±0.7 0.0001 0.2 
L2/L3 VAT (cm
2
) 78±74 92±75 105±76 116±72 0.0001 0.4 
L2/L3 SAT (cm
2
) 151±89 167±85 183±83 203±87 0.0001 0.5 
L4/L5 VAT (cm
2
) 68±44 76±43 89±50 101±51 0.0001 0.6 
L4/L5 SAT (cm
2
) 243±105 263±105 275±106 294±103 0.0001 0.9 
L4/L5 SSAT (cm
2





123±54 133±52 146±52 154±55 0.001 0.7 
Liver density  
(HU) 
58±5 55±4 51±16 48±16 0.0001 0.6 
Fat cell size (µm) 58±7 58±5 60±6 59±8 0.5 0.8 
VAT- visceral adipose tissue, SAT- subcutaneous adipose tissue, SSAT- superficial 349 
subcutaneous adipose tissue, DSAT- deep subcutaneous adipose tissue 350 




Figure Legend: 353 
Fig 1 Study timeline and food consumption regimen. From day -3 to the baseline study, all 354 
foods were provided to subjects at calculated baseline energy requirements (A; 30% fat, 15% 355 
protein and 55% carbohydrates). During the overfeeding phase (in grey), on days 0 – 3 and 356 
25 – 28, all foods were provided to subjects at calculated baseline energy requirements + 357 
1250 kcal/d (B; 45% fat, 15% protein and 40% carbohydrates). On days 3 – 25, subjects were 358 
instructed to consume their regular diets and were provided with high fat snacks to provide 359 
additional 1250 kcal/day (C).  360 
 361 
Fig 2 Weight, circulating hormones and metabolites, HOMA-IR and respiratory 362 
quotient at baseline and in response to overfeeding Weight (A), serum leptin (B), glucose 363 
(C), insulin (D), C-peptide (E), HOMA-IR (F), NEFA (G) and RQ (H) at baseline and at +3- 364 
and +28- days of overfeeding in subjects with (white squares) and without (black squares) a 365 
family history of type 2 diabetes. Difference from baseline *p < 0.05, **p < 0.005; difference 366 
between groups 
#
p < 0.05, 
##
p < 0.01, 
δ
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